[Epidemiology of drug-resistant HIV-1 transmission in naïve patients in Spain].
HIV-1 drug-resistance transmission compromises the effectiveness of antiretroviral therapy. Thus, epidemiological studies of resistance in naïve patients acquire a major relevance for the first treatment design. However, their methodological heterogeneity complicates the comparison of results. The global transmitted primary resistance prevalence in Spain from 1997 through 2008 was 10.6%, similar to the rest of Europe. Regarding drug families, prevalence was 5.8% for NRTI, 5% for NNRTI and 3.8% for PI. In further studies, it should be considered: i) to homogenize resistance testing favouring genetic sequencing instead of other methods and to improve minority resistances detection; ii) to create a unique mutations list to be applied to all HIV-1 variants; iii) to be aware of the circulating subtypes and established therapy in the areas of infection that could determine the resistance pattern; and iv) to promote multicenter studies including representative and numerous populations.
Yebra
Gonzalo
G
Laboratorio de Epidemiología Molecular del virus de la inmunodeficiencia humana de tipo 1, Servicio de Microbiología, Hospital Ramón y Cajal, CIBER-ESP, Madrid, Spain.
Holguín
Africa
A
D044966:Anti-Retroviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000235:genetics / Q000635:transmission; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D009154:Mutation; D015995:Prevalence; D013030:Spain / Q000453:epidemiology
D044966:Anti-Retroviral Agents